BRPI0907162A2 - Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero - Google Patents

Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero

Info

Publication number
BRPI0907162A2
BRPI0907162A2 BRPI0907162-8A BRPI0907162A BRPI0907162A2 BR PI0907162 A2 BRPI0907162 A2 BR PI0907162A2 BR PI0907162 A BRPI0907162 A BR PI0907162A BR PI0907162 A2 BRPI0907162 A2 BR PI0907162A2
Authority
BR
Brazil
Prior art keywords
performer
mammal
treating
compound
methods
Prior art date
Application number
BRPI0907162-8A
Other languages
English (en)
Inventor
Jim Wells
Adam R Renslo
Denis Wolan
Julie Zorn
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0907162A2 publication Critical patent/BRPI0907162A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0907162-8A 2008-01-11 2009-01-09 Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero BRPI0907162A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2060808P 2008-01-11 2008-01-11
PCT/US2009/030680 WO2009089508A1 (en) 2008-01-11 2009-01-09 Activators of executioner procaspases 3, 6 and 7

Publications (1)

Publication Number Publication Date
BRPI0907162A2 true BRPI0907162A2 (pt) 2015-07-07

Family

ID=40853483

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907162-8A BRPI0907162A2 (pt) 2008-01-11 2009-01-09 Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero

Country Status (11)

Country Link
US (1) US8642788B2 (pt)
EP (1) EP2237784A1 (pt)
JP (1) JP2011509939A (pt)
CN (1) CN101965189A (pt)
AU (1) AU2009203977A1 (pt)
BR (1) BRPI0907162A2 (pt)
CA (1) CA2711603A1 (pt)
EA (1) EA201001143A1 (pt)
IL (1) IL206901A0 (pt)
MX (1) MX2010007548A (pt)
WO (1) WO2009089508A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9825331B2 (en) * 2011-11-30 2017-11-21 Solvay Sa Fluorinated derivatives of meldrum's acid, a method for the preparation of the same, and their use as a solvent additive
WO2013131089A2 (en) * 2012-03-02 2013-09-06 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
CN104540501B (zh) 2012-03-06 2016-11-23 伊利诺伊大学评议会 用于胶质母细胞瘤的半胱天冬酶酶原结合的疗法
IN2014MN01945A (pt) 2012-03-06 2015-07-10 Univ Illinois
CN104144919B (zh) * 2012-09-27 2018-07-03 山东营东颖昊生物科技有限公司 茶氨酸衍生物与羧酸香豆素衍生物的缩合产物及其中间体、其制备方法和用途
JP6321042B2 (ja) 2013-02-06 2018-05-09 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規なハロゲン置換された化合物
MX2016006976A (es) 2013-11-27 2016-09-07 Bayer Cropscience Ag Proceso para la preparacion de 5-fluoro-1h-pirazoles.
BR112016017527B1 (pt) 2014-01-03 2021-01-05 Bayer Animal Health Gmbh compostos, usos de compostos, composições farmacêuticas, processo para produzir composições e método não terapêutico para controlar pragas
EP3183237B1 (en) 2014-08-19 2019-07-24 Bayer Animal Health GmbH Process for the preparation of 5-fluoro-1h-pyrazoles starting from hexafluoropropene
ES2836399T3 (es) 2015-03-10 2021-06-25 Bayer Animal Health Gmbh Derivados de pirazolilo como agentes de control de plagas
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
CN106946897B (zh) * 2017-02-28 2018-10-23 牡丹江医学院 一种治疗胆囊炎的药物及其应用
CA3082575A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CR20220066A (es) 2019-08-14 2022-11-28 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US20230092441A1 (en) * 2019-12-24 2023-03-23 The Regents Of The University Of California Compositions and methods for treating cancer and improving epithelial homeostasis
AU2021274818A1 (en) 2020-05-20 2022-09-29 AMO Ireland Azacoumarin and azathiocoumarin derivatives for use in optically active devices
CN113024499A (zh) * 2021-03-17 2021-06-25 河南中烟工业有限责任公司 一种香豆素-3-羧酸类化合物的绿色合成方法
JP2024522192A (ja) 2021-06-14 2024-06-11 スコーピオン セラピューティクス インコーポレイテッド がんを処置するために使用され得る尿素誘導体
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024129896A1 (en) * 2022-12-14 2024-06-20 The Regents Of The University Of California Inhibitors of procaspase-6 activation and uses thereof
CN117186001B (zh) * 2023-09-07 2024-09-17 南京中医药大学 一种具有抗多发性骨髓瘤活性的aha1抑制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342516B1 (en) * 1998-07-31 2002-01-29 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
AU2001277731A1 (en) * 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
US20030229132A1 (en) * 2002-02-12 2003-12-11 Jack Nguyen Small molecule modulators of apoptosis
KR100440588B1 (ko) * 2002-06-10 2004-07-19 한국전자통신연구원 계층적 구조를 지원하는 직렬 버스형 형상 인식 및 경보장치
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
US20110021522A1 (en) 2011-01-27
MX2010007548A (es) 2010-11-25
EA201001143A1 (ru) 2011-02-28
AU2009203977A1 (en) 2009-07-16
CN101965189A (zh) 2011-02-02
CA2711603A1 (en) 2009-07-16
JP2011509939A (ja) 2011-03-31
EP2237784A1 (en) 2010-10-13
US8642788B2 (en) 2014-02-04
WO2009089508A1 (en) 2009-07-16
IL206901A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
BRPI0907162A2 (pt) Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0812521A2 (pt) Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0812851A2 (pt) Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
CR10667A (es) Compositions and methods for diagnosing and treating cancer
BRPI0915284A2 (pt) Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral
BRPI0813011A2 (pt) Formulação injetável aquosa estéril, processo de preparação da mesma e sua utilização
BRPI0809890A2 (pt) Processo para preparar imatinib ou sal do mesmo e composição farmacêutica
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0618845A2 (pt) composto, formulação farmacêutica, uso de um composto, e, métodos para a inibição da atividade de bace e para o tratamento ou a prevenção de uma patologia relacionada a abeta em um mamífero
BRPI0912245A2 (pt) composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
PL2578081T3 (pl) Kompozycje, sposoby i urządzenia do leczenia chorób wątroby
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
EP1962873A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE RELATED DISEASE
BRPI0911681A2 (pt) composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula
BRPI0817448A2 (pt) Composto, composição farmacêutica, método para prevenção ou tratamento de uma condição patológica ou sintoma em um mamífero, uso de um composto, e, kit
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0906805A2 (pt) Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação
BRPI0822095A2 (pt) Método para reduzir o sangramento e/ou hematoma em um paciente
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.